To determine whether arming with IL-24 or ING4 therapeutic genes leads to improved oncolytic CRAd potency we tested cell viability and cytotoxicity following infection of normal and ovarian cancer (OvCa) cells. Here, IL24 is linked to ovarian carcinoma.